Q4 2022 Results

Company overview Financial review 2023 priorities Appendix Leqvio® – we are continuing to progress the launch in Q4... - GROWTH LEQVIO® Addressing non-clinical barriers Access Patients covered at or near label1 76% Adoption Facilities having ordered LeqvioⓇ +21% Adherence Patients coming for 2nd dose within <95 days4 Adoption 75% HCPS3 with LeqvioⓇ experience +50% FY sales USD 112 million ORION-3 data and publication ■ Strong long-term safety profile ■ Effective/sustained reductions in LDL-C over 4 years ■ At any time throughout the trial -80% of patients reached LDL-C <70mg/dL Ph3 secondary prevention CVRR studies (ORION-4/V2P) ongoing Ph3 primary prevention CVRR study expected start H1 2023 1,700 1,400 7,200 4,800 Q3 2022 HCP Q3 2022 Q4 2022 healthcare professional. Q4 2022 *Leqvio® is administered initially, again V2P-VICTORION-2-PREVENT. 1. As of January 3, 2022. 2. Either an alternate site of care or a physician practice. 3. Either prescribe LeqvioⓇ to a patient based on service center data, data on file or 4. Refers to average duration in between doses. Based on IQVIA and data shared by infusion management and ambulatory infusion center companies. **Novartis has obtained global rights to develop, manufacture and commercialize LeqvioⓇ under a license agreement with Alnylam Pharmaceuticals. have ordered through Free Trial Offer program. at 3 months, and then once every 6 months. 29 Investor Relations | Q4 2022 Results ✓ NOVARTIS | Reimagining Medicine

View entire presentation